Dishman Carbogen (DCAL) | Stock Overview & Key Data
Dishman Carbogen Performance Comparison
Stock Range
Today's Range
Low: ₹234.20
High: ₹244.95
on August 11, 2025
52 Week Range
Low: ₹161.21
High: ₹307.98
on October 7, 2024
on December 11, 2024
All-Time High: ₹396.40 on January 22, 2018
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR36.7B
EPS
0.21
P/E Ratio (TTM)
1,114.29
Forward P/E
18.72
P/B Ratio
0.63
PEG Ratio
18.72
Div. Yield
N/A
ROE
0.06%
Beta
0.169
Debt to Equity
40.97
Financial Highlights
Profitability
Gross Margin
79.63%
Operating Margin
10.27%
Profit Margin
0.12%
Returns and Earnings
Return on Assets (TTM)
1.12%
Return on Equity (TTM)
0.06%
EBITDA
INR4.9B
Net Income (TTM)
INR32.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR172.95
Quarterly Revenue Growth (YoY)
9.40%
Quarterly Earnings Growth (YoY)
22.96%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Dishman Carbogen DCAL | 36.69B Small-cap | -3.47% | -8.84% | 27.79% | -2.26% | -17.23% | 22.14% | 106.15% | 27.13% |
| Biocon BIOCON | 456.09B Large-cap | -10.38% | -7.04% | 2.62% | -8.96% | -6.90% | 1.90% | 10.35% | -13.10% |
| OneSource Specialty ONESOURCE | 216.76B Large-cap | 1.94% | -5.48% | 18.19% | 22.64% | 10.61% | 10.61% | 10.61% | 10.61% |
| Zota Health Care ZOTA | 31.09B Small-cap | -0.78% | -2.36% | 45.12% | 25.14% | 50.88% | 85.82% | 335.52% | 755.41% |
| Panacea Biotec PANACEABIO | 25.12B Small-cap | 2.01% | 1.32% | -18.83% | 4.32% | -6.84% | 204.85% | 215.33% | 148.03% |
| 3B Blackbio 3BBLACKBIO | 12.96B Small-cap | -2.02% | -5.28% | -10.94% | -17.25% | -22.10% | 27.91% | 92.96% | 92.96% |
Ownership & Short Interest
Insider Ownership
70.66%
Institutional Ownership
2.24%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
94K
Average 90-Day Volume
90K
Dishman Carbogen Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Dishman Carbogen would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is DCAL's 52-week high and low?
- In the last 52 weeks, Dishman Carbogen reached a high of ₹307.98 (on December 11, 2024) and a low of ₹161.21 (on October 7, 2024).
- What is the market cap and P/E ratio for DCAL?
- Curious about Dishman Carbogen's size and valuation? Its market capitalization stands at 36.69B. When it comes to valuation, the P/E ratio (trailing twelve months) is 1,114.29, and the forward P/E (looking ahead) is 18.72.
- Does DCAL pay dividends? If so, what's the yield?
- As for dividends, Dishman Carbogen isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dishman Carbogen's main competitors or similar companies to consider before investing?
When looking at Dishman Carbogen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON456.09B Healthcare Biotechnology 1.90% 10.35% OneSource Specialty
ONESOURCE216.76B Healthcare Biotechnology 10.61% 10.61% Zota Health Care
ZOTA31.09B Healthcare Biotechnology 85.82% 335.52% Panacea Biotec
PANACEABIO25.12B Healthcare Biotechnology 204.85% 215.33% 3B Blackbio
3BBLACKBIO12.96B Healthcare Biotechnology 27.91% 92.96% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dishman Carbogen Amcis Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Dishman Carbogen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 0.06%, the Debt to Equity ratio from the most recent quarter is 40.97, and its Gross Profit Margin stands at 79.63%.
- What is the recent revenue and earnings growth for DCAL?
- Looking at Dishman Carbogen's growth, its revenue over the trailing twelve months (TTM) was INR27B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.40%, and quarterly earnings saw a YoY growth of 22.96%.
- How much of DCAL stock is held by insiders and institutions?
- Wondering who owns Dishman Carbogen stock? Company insiders (like executives and directors) hold about 70.66% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 2.24%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.